A Phase 2 interventional study of Tenofovir disoproxil fumarate (tenofovir DF; TDF) and Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in Chronic Hepatitis B, sponsored by Gilead Sciences. Completed at 38 sites in 11 countries. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2013-04-25.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 28th largest by enrollment, is one of 2 that started in 2006, is one of 4 in phase 2, and was the 3rd registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 2 started in 2006.
This study's enrollment of 112 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
34 studies in Hepatitis B, Chronic by Gilead Sciences: none open now, 2 under way, 1 of them phase 3. Of 31 finished, 24 (77%) have results posted.
Among the 34 studies in Hepatitis B, Chronic by Gilead Sciences, this one is the 15th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2006, is one of 15 in phase 2, and was the 9th registered.
Gilead Sciences’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 34 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
This study was designed to evaluate and compare the safety and tolerability of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC)/TDF, and entecavir (ETV) in the treatment of hepatitis B patients with decompensated liver disease. Safety was assessed by evaluating adverse events (AEs) and laboratory abnormalities. Efficacy was assessed by evaluating reductions in Child-Pugh-Turcotte (CPT) and Model for End Stage Liver Disease (MELD) scores, reductions in hepatitis B virus (HBV) deoxyribonucleic acid (DNA), changes in liver enzymes, development of drug-resistant mutations, and generation of antibody to virus.
A maximum randomized treatment duration of 168 weeks was planned. Since subjects with decompensated liver disease were enrolled into this study, it was necessary to provide early intervention strategies if profound viral suppression was not expeditiously achieved. For this reason, subjects with a decrease in plasma HBV DNA from baseline of \< 2 log_10 copies/mL and plasma HBV DNA > 10,000 copies/mL (or plasma HBV DNA > 1,000 copies/mL for subjects who entered the study with HBV DNA \< 10,000 copies/mL) at Week 8 had the option to start open-label FTC/TDF and continue in the study. Subjects with a virologic breakthrough or who had plasma HBV DNA levels remaining > 400 copies/mL (confirmed) at or after 24 weeks of treatment could have been unblinded at the investigator's discretion for selection of alternative anti-HBV therapy that may have included open-label FTC/TDF. If study drug was permanently discontinued, immediate initiation of another anti-HBV regimen was strongly recommended.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A participant was required to meet all of the following inclusion criteria to be eligible for participation in the study:
Decompensated liver disease with all of the following:
Exclusion Criteria:
A participant who met any of the following exclusion criteria could not be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TDF 300 mg + FTC/TDF placebo + ETV placebo once daily (QD)
Drug: Tenofovir disoproxil fumarate (tenofovir DF; TDF) · Drug: FTC/TDF placebo · Drug: ETV placebo
FTC 200 mg/TDF 300 mg + TDF placebo + ETV placebo QD
Drug: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) · Drug: TDF placebo · Drug: ETV placebo
ETV 0.5 mg or 1 mg + TDF placebo + FTC/TDF placebo QD
Drug: Entecavir (ETV) · Drug: TDF placebo · Drug: FTC/TDF placebo
300-mg tablet QD
Also known as: Viread
FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
Also known as: Truvada
0.5-mg or 1-mg tablet QD
Also known as: Baraclude
Placebo to match TDF QD
Placebo to match FTC/TDF QD
Placebo to match ETV QD
Percent Probability of Tolerability Failure
Tolerability failure was defined as permanent discontinuation of study drug due to a treatment-emergent adverse event (AE), including any subject who temporarily discontinued study drug due to an AE and did not restart. Results are expressed as proportions of participants who experience tolerability failure using the Kaplan-Meier (KM) method of estimation.
Time frame: Baseline to Week 168
Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL
Results are expressed as proportions of participants who experience a confirmed increase in serum creatinine of ≥ 0.5 mg/dL from baseline or a confirmed serum phosphorus level \< 2.0 mg/dL using the KM method of estimation.
Time frame: Baseline to Week 168
Median Time-averaged Change (DAVG) in Plasma Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels at 48 Weeks Relative to Baseline
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 48 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
Time frame: Baseline to 48 weeks
Median DAVG in Plasma HBV DNA Levels at 96 Weeks Relative to Baseline
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 96 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
Time frame: Baseline to 96 weeks
Median DAVG in Plasma HBV DNA Levels at 144 Weeks Relative to Baseline
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 144 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
Time frame: Baseline to 144 weeks
Median DAVG in Plasma HBV DNA Levels at 168 Weeks Relative to Baseline
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 168 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
Time frame: Baseline to 168 weeks
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 48 was summarized.
Time frame: Week 48
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 96
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 96 was summarized.
Time frame: Week 96
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 144
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 144 was summarized.
Time frame: Week 144
Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 168 was summarized.
Time frame: Week 168
Percentage of Participants With Normalized Alanine Aminotransferase (ALT) (for Subjects With Elevated ALT at Baseline) at Week 48
Normalized ALT is defined as having a baseline ALT value \> the upper limit of the normal range (ULN), and a decrease in ALT value to ≤ ULN at the given time point.
Time frame: Baseline to Week 48
Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 96
Normalized ALT is defined as having a baseline ALT value \> ULN, and a decrease in ALT value to ≤ ULN at the given time point.
Time frame: Baseline to Week 96
Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 144
Normalized ALT is defined as having a baseline ALT value \> ULN, and a decrease in ALT value to ≤ ULN at the given time point.
Time frame: Baseline to Week 144
Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 168
Normalized ALT is defined as having a baseline ALT value \> ULN, and a decrease in ALT value to ≤ ULN at the given time point.
Time frame: Baseline to Week 168
Percentage of Participants With an Increase in Child-Pugh Turcotte (CPT) Score of ≥ 2 Points at Weeks 48
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 48
Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 96
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 96
Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 144
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 144
Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 168
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 168
Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 48
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 48
Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 96
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 96
Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 144
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 144
Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 168
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
Time frame: Baseline to Week 168
Median Change in Model for End-Stage Liver Disease (MELD) Score From Baseline at Week 48
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
Time frame: Baseline to Week 48
Median Change in MELD Score From Baseline at Week 96
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
Time frame: Baseline to Week 96
Median Change in MELD Score From Baseline at Week 144
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
Time frame: Baseline to Week 144
Median Change in MELD Score From Baseline at Week 168
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
Time frame: Baseline to Week 168
Percentage of Participants With Hepatitis B Early Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 48 (for Participants Who Were HBeAg Positive at Baseline)
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
Time frame: Baseline to Week 48
Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 96 (for Participants Who Were HBeAg Positive at Baseline)
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
Time frame: Baseline to Week 96
Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 144 (for Participants Who Were HBeAg Positive at Baseline)
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
Time frame: Baseline to Week 144
Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 168 (for Participants Who Were HBeAg Positive at Baseline)
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
Time frame: Baseline to Week 168
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Week 48
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
Time frame: Baseline to Week 48
Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 96
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
Time frame: Baseline to Week 96
Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 144
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
Time frame: Baseline to Week 144
Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 168
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
Time frame: Baseline to Week 168
In the Subset of Participants Undergoing Liver Transplantation, Time to Recurrence of Hepatitis B, Defined as 2 Consecutive Plasma HBV DNA Concentrations ≥ 400 Copies/mL or 2 Consecutive HBsAg(+) Results
Time frame: Baseline to Week 168
Percentage of Participants With Only Baseline Adefovir Dipivoxil Resistance (ADV-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
ADV resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation.
Time frame: Baseline to Week 168
Percentage of Participants With Only Baseline Lamivudine-resistance (LAM-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
LAM resistance mutations are defined as the presence of the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation.
Time frame: Baseline to Week 168
Percentage of Participants With Baseline ADV-R + LAM-R Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
ADV resistance mutation + LAM resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation, and the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation.
Time frame: Baseline to Week 168
Of the 112 participants randomized, 43 were in Taiwan or Singapore, 43 were in Europe (Turkey, Spain, Germany, Greece, Poland, Italy, or France), and 26 were in the US or Canada. The first participant was screened on 04 April 2006, and the last participant was randomized on 03 January 2008. Last participant observation date was 12 April 2011.
| Milestone | Tenofovir DF | FTC/TDF | Entecavir |
|---|---|---|---|
| Started | 45 | 45 | 22 |
| Completed | 28 | 37 | 16 |
| Not completed | 17 | 8 | 6 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Physician decision | 4 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 | 3 |
| Withdrew: Adverse event | 5 | 2 | 2 |
| Withdrew: Lack of efficacy | 2 | 3 | 0 |
Tolerability failure was defined as permanent discontinuation of study drug due to a treatment-emergent adverse event (AE), including any subject who temporarily discontinued study drug due to an AE and did not restart. Results are expressed as proportions of participants who experience tolerability failure using the Kaplan-Meier (KM) method of estimation.
| percent probability (KM estimate) | Tenofovir DF | FTC/TDF | TDF or FTC/TDF | Entecavir |
|---|---|---|---|---|
| Percent Probability of Tolerability Failure | 18 (5.8 to 30.6) | 4 (0.0 to 10.4) | 11 (4.1 to 17.7) | 14 (0.0 to 29.5) |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 48 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
| log_10 copies/mL | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median Time-averaged Change (DAVG) in Plasma Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels at 48 Weeks Relative to Baseline | -2.93 (-3.84 to -2.18) | -3.45 (-4.73 to -2.02) | -3.61 (-4.51 to -1.31) | -3.19 (-4.52 to -2.08) |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 96 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
| log_10 copies/mL | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median DAVG in Plasma HBV DNA Levels at 96 Weeks Relative to Baseline | -3.06 (-4.17 to -2.18) | -4.06 (-4.97 to -2.38) | -3.32 (-4.82 to -1.26) | -3.40 (-4.81 to -2.14) |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 144 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
| log _10 copies/mL | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median DAVG in Plasma HBV DNA Levels at 144 Weeks Relative to Baseline | -3.07 (-4.36 to -2.00) | -3.82 (-4.99 to -2.06) | -3.76 (-5.00 to -1.33) | -3.49 (-4.91 to -2.05) |
Change from baseline was evaluated by subtracting baseline HBV DNA log_10 copies/mL from Week 168 HBV DNA log_10 copies/mL. DAVG is defined as the area of the trapezoid under the response-time curve divided by time to the last available evaluation of the patient minus the baseline value.
| log_10 copies/mL | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median DAVG in Plasma HBV DNA Levels at 168 Weeks Relative to Baseline | -3.16 (-4.57 to -1.97) | -4.06 (-5.15 to -2.42) | -3.77 (-5.02 to -1.33) | -3.66 (-4.99 to -2.10) |
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 48 was summarized.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48 | 70.5 | 87.8 | 72.7 | 77.6 |
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 96 was summarized.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 96 | 59.1 | 79.5 | 57.1 | 66.3 |
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 144 was summarized.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 144 | 50.0 | 77.5 | 52.4 | 61.0 |
The percentage of participants with plasma HBV DNA \< 400 copies/mL at Week 168 was summarized.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168 | 50.0 | 75.7 | 52.4 | 60.0 |
Normalized ALT is defined as having a baseline ALT value \> the upper limit of the normal range (ULN), and a decrease in ALT value to ≤ ULN at the given time point.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Normalized Alanine Aminotransferase (ALT) (for Subjects With Elevated ALT at Baseline) at Week 48 | 46.2 | 64.0 | 41.2 | 51.5 |
Normalized ALT is defined as having a baseline ALT value \> ULN, and a decrease in ALT value to ≤ ULN at the given time point.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 96 | 50.0 | 58.3 | 31.3 | 48.5 |
Normalized ALT is defined as having a baseline ALT value \> ULN, and a decrease in ALT value to ≤ ULN at the given time point.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 144 | 34.6 | 64.0 | 37.5 | 46.3 |
Normalized ALT is defined as having a baseline ALT value \> ULN, and a decrease in ALT value to ≤ ULN at the given time point.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 168 | 29.2 | 60.0 | 37.5 | 43.1 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With an Increase in Child-Pugh Turcotte (CPT) Score of ≥ 2 Points at Weeks 48 | 0.0 | 2.6 | 0.0 | 1.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 96 | 0.0 | 0.0 | 0.0 | 0.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 144 | 0.0 | 2.5 | 0.0 | 1.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 168 | 2.4 | 0.0 | 0.0 | 1.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 48 | 25.9 | 48.0 | 41.7 | 37.5 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 96 | 23.1 | 52.0 | 50.0 | 39.3 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 144 | 25.9 | 51.9 | 45.5 | 40.0 |
CPT scores, widely used to grade the severity of cirrhosis and to determine the need for liver transplantation, are calculated based on a combination of laboratory values and clinical features. CPT scores can range from 5 to 15, with higher scores indicating a greater severity of disease.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 168 | 24.0 | 45.8 | 45.5 | 36.7 |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
| units on a scale | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median Change in Model for End-Stage Liver Disease (MELD) Score From Baseline at Week 48 | -2.0 (-3.0 to 0.0) | -2.0 (-4.0 to 0.0) | -2.0 (-4.0 to -1.0) | -2.0 (-3.0 to 0.0) |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
| units on a scale | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median Change in MELD Score From Baseline at Week 96 | -2.0 (-3.0 to 1.0) | -3.0 (-4.0 to 0.0) | -3.0 (-4.0 to -1.0) | -2.0 (-4.0 to 0.0) |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
| units on a scale | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median Change in MELD Score From Baseline at Week 144 | -2.0 (-3.5 to -0.5) | -1.5 (-6.0 to 0.0) | -2.0 (-5.0 to -1.0) | -2.0 (-4.0 to 0.0) |
MELD scores, used to assess prognosis and suitability for transplant, are calculated based on laboratory values only and can range from 6 to 40, with higher scores indicating greater disease severity.
| units on a scale | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| Median Change in MELD Score From Baseline at Week 168 | -2.0 (-4.0 to -1.0) | -2.0 (-4.0 to 0.0) | -2.0 (-5.0 to 0.0) | -2.0 (-4.0 to 0.0) |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBeAg Loss | 21.4 | 26.7 | 0.0 | 19.4 |
| HBeAg Seroconversion | 21.4 | 13.3 | 0.0 | 13.9 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBeAg Loss | 14.3 | 33.3 | 0.0 | 20.0 |
| HBeAg Seroconversion | 14.3 | 13.3 | 0.0 | 11.4 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBeAg Loss | 14.3 | 33.3 | 16.7 | 22.9 |
| HBeAg Seroconversion | 14.3 | 13.3 | 0.0 | 11.4 |
Loss of HBeAg was defined as change of detectable HBeAg from positive to negative. HBeAg seroconversion was defined as change of detectable antibody to HBeAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBeAg Loss | 23.1 | 35.7 | 16.7 | 27.3 |
| HBeAg Seroconversion | 23.1 | 21.4 | 0.0 | 18.2 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBsAg Loss | 0.0 | 0.0 | 0.0 | 0.0 |
| HBsAg Seroconversion | 0.0 | 0.0 | 0.0 | 0.0 |
ADV resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir |
|---|---|---|---|
| Percentage of Participants With Only Baseline Adefovir Dipivoxil Resistance (ADV-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks | 100 | 100 | — |
LAM resistance mutations are defined as the presence of the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir |
|---|---|---|---|
| Percentage of Participants With Only Baseline Lamivudine-resistance (LAM-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks | 100 | 100 | 100 |
ADV resistance mutation + LAM resistance mutations are defined as the presence of the rtA181T/V HBV gene mutation and/or the rtN236T HBV gene mutation, and the rtM204V/I HBV gene mutation with or without the rtL180M HBV gene mutation.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir |
|---|---|---|---|
| Percentage of Participants With Baseline ADV-R + LAM-R Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks | 50 | — | — |
Results are expressed as proportions of participants who experience a confirmed increase in serum creatinine of ≥ 0.5 mg/dL from baseline or a confirmed serum phosphorus level \< 2.0 mg/dL using the KM method of estimation.
| percent probability (KM estimate) | Tenofovir DF | FTC/TDF | TDF or FTC/TDF | Entecavir |
|---|---|---|---|---|
| Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL | 15 (3.9 to 25.9) | 14 (3.6 to 24.4) | 14 (6.8 to 22.0) | 10 (0.0 to 22.8) |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBsAg Loss | 0.0 | 0.0 | 0.0 | 0.0 |
| HBsAg Seroconversion | 0.0 | 0.0 | 0.0 | 0.0 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBsAg Loss | 0.0 | 0.0 | 0.0 | 0.0 |
| HBsAg Seroconversion | 0.0 | 0.0 | 0.0 | 0.0 |
Loss of HBsAg was defined as change of detectable HBsAg from positive to negative. HBsAg seroconversion was defined as change of detectable antibody to HBsAg from negative to positive.
| percentage of participants | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| HBsAg Loss | 0.0 | 0.0 | 0.0 | 0.0 |
| HBsAg Seroconversion | 0.0 | 0.0 | 0.0 | 0.0 |
| Days | Tenofovir DF | FTC/TDF | Entecavir | Overall |
|---|---|---|---|---|
| In the Subset of Participants Undergoing Liver Transplantation, Time to Recurrence of Hepatitis B, Defined as 2 Consecutive Plasma HBV DNA Concentrations ≥ 400 Copies/mL or 2 Consecutive HBsAg(+) Results | NA | NA | NA | NA |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind TDF | — | 21/45 (46.7%) | 41/45 (91.1%) |
| Double Blind FTC/TDF | — | 25/45 (55.6%) | 44/45 (97.8%) |
| Double Blind ETV | — | 11/22 (50%) | 20/22 (90.9%) |
| Open Label FTC/TDF | — | 4/12 (33.3%) | 9/12 (75%) |
| All TDF | — | 50/93 (53.8%) | 89/93 (95.7%) |
| Event | Double Blind TDF | Double Blind FTC/TDF | Double Blind ETV | Open Label FTC/TDF | All TDF |
|---|---|---|---|---|---|
| Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/45 | 3/45 | 2/22 | 1/12 | 12/93 |
| Hepatic function abnormalHepatobiliary disorders | 2/45 | 5/45 | 2/22 | 0/12 | 7/93 |
| Hepatic encephalopathyNervous system disorders | 3/45 | 1/45 | 2/22 | 0/12 | 4/93 |
| AscitesGastrointestinal disorders | 3/45 | 3/45 | 1/22 | 1/12 | 7/93 |
| CholestasisHepatobiliary disorders | 0/45 | 0/45 | 0/22 | 1/12 | 1/93 |
| Hepatitis acuteHepatobiliary disorders | 0/45 | 0/45 | 0/22 | 1/12 | 1/93 |
| Pyelonephritis acuteInfections and infestations | 0/45 | 0/45 | 0/22 | 1/12 | 1/93 |
| Biliary anastomosis complicationInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/22 | 1/12 | 1/93 |
| Calculus UretericRenal and urinary disorders | 0/45 | 0/45 | 0/22 | 1/12 | 1/93 |
| HydronephrosisRenal and urinary disorders | 0/45 | 0/45 | 0/22 | 1/12 | 1/93 |
| Event | Double Blind TDF | Double Blind FTC/TDF | Double Blind ETV | Open Label FTC/TDF | All TDF |
|---|---|---|---|---|---|
| AscitesGastrointestinal disorders | 8/45 | 4/45 | 6/22 | 1/12 | 13/93 |
| DiarrhoeaGastrointestinal disorders | 4/45 | 1/45 | 5/22 | 1/12 | 5/93 |
| Oedema peripheralGeneral disorders | 8/45 | 3/45 | 5/22 | 0/12 | 11/93 |
| HeadacheNervous system disorders | 4/45 | 3/45 | 5/22 | 1/12 | 8/93 |
| Abdominal pain upperGastrointestinal disorders | 9/45 | 7/45 | 2/22 | 2/12 | 18/93 |
| NauseaGastrointestinal disorders | 9/45 | 3/45 | 1/22 | 0/12 | 12/93 |
| InsomniaPsychiatric disorders | 9/45 | 4/45 | 4/22 | 1/12 | 14/93 |
| PyrexiaGeneral disorders | 6/45 | 5/45 | 4/22 | 0/12 | 11/93 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/45 | 4/45 | 4/22 | 2/12 | 8/93 |
| Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/45 | 3/45 | 2/22 | 1/12 | 12/93 |
| Age Continuous(years) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| Mean | 53 ± 8.8 | 49 ± 10.1 | 52 ± 12.0 | 51 ± 10.0 |
| Sex: Female, Male(Participants) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| Female | 8 | 5 | 5 | 18 |
| Male | 37 | 40 | 17 | 94 |
| Region of Enrollment(participants) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| France | 0 | 0 | 1 | 1 |
| United States | 10 | 2 | 2 | 14 |
| Taiwan | 13 | 16 | 9 | 38 |
| Greece | 4 | 1 | 1 | 6 |
| Canada | 4 | 7 | 1 | 12 |
| Poland | 2 | 2 | 2 | 6 |
| Spain | 2 | 6 | 2 | 10 |
| Singapore | 1 | 3 | 1 | 5 |
| Turkey | 4 | 6 | 2 | 12 |
| Germany | 4 | 1 | 1 | 6 |
| Italy | 1 | 1 | 0 | 2 |
| Race(participants) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| Asian | 23 | 24 | 13 | 60 |
| Black | 1 | 1 | 0 | 2 |
| Other | 2 | 0 | 1 | 3 |
| White | 19 | 20 | 8 | 47 |
| Ethnicity(participants) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 0 | 3 |
| Not Hispanic or Latino | 39 | 39 | 21 | 99 |
| Not Permitted | 4 | 5 | 1 | 10 |
| Weight(kg) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| Mean | 78.1 ± 17.02 | 74.4 ± 15.41 | 77.3 ± 16.64 | 76.5 ± 16.26 |
| Height(cm) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| Mean | 168.3 ± 7.98 | 168.4 ± 8.47 | 167.1 ± 8.39 | 168.1 ± 8.20 |
| BMI(kg/m^2) | Tenofovir DF | FTC/TDF | Entecavir | Total |
|---|---|---|---|---|
| Mean | 27.6 ± 5.67 | 26.2 ± 5.07 | 27.6 ± 5.27 | 27.0 ± 5.35 |
The record gives a start of Apr 2006, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2013, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tenofovir · Entecavir